The G4 Cancer Cure, a new project developing a treatment for aggressive breast cancer, has recently joined the Umeå Biotech Incubator.
“We are extremely happy and look forward to some exciting times ahead. This is an important step for us in the development of our product,” says Associate Professor Nasim Sabouri, one of the project’s three owners.
The goal of the G4 Cancer Cure is to develop a new treatment for triple-negative breast cancer. The project is based on years of research from Umeå University in Sweden conducted by biochemist Nasim Sabouri, chemist Erik Chorell and cell biologist Sjoerd Wanrooij. Project manager for the G4 Cancer Cure is Milada Jamroskovic, who has a background in business administration.
“Triple-negative breast cancer is an aggressive type of cancer with a worse prognosis than other forms of breast cancer. We have a new prototype of a cancer drug that effectively kills this aggressive type of breast cancer by simultaneously attacking two different biological mechanisms linked to cancer,” says Sjoerd Wanrooij.
The project has now been welcomed into Umeå Biotech Incubator (UBI), which helps promising life science ideas with financing and business support, as well as laboratory equipment and office facilities.
“This is very positive news and promises to be an extremely informative time for us, where we can develop our product with the support and expertise from UBI,” says Erik Chorell.
The contact person at Umeå Biotech Incubator is business coach Peter Jacobsson, who has extensive experience in business support and drug development.
‘This is an exciting cancer project with promising results that can make a real difference. It has also received a positive response from prospective customers and investors. I’m confident that we at Umeå Biotech Incubator, together with our network of expertise within pharmaceutical and business development, can help the project reach its full potential,” says Peter Jacobsson.
Some of the advantages of G4 Cancer Cure's new treatment are that side effects are reduced, the risk of drug resistance is lower and production costs are less than for other treatment methods.
“We want to develop our prototype and take it all the way to drug development and into hospitals as a new treatment method. Our goal is to help as many people as possible suffering from this serious form of cancer,” says Milada Jamroskovic, and continues:
“Thanks to the combination of brilliant research and support from Umeå Biotech Incubator our chances of success have never been better.”
For further information please contact:
Milada Jamroskovic, Project Manager.
+46 (0)70 234 76 83
Umeå Biotech Incubator (UBI) is one of Sweden’s state-of-the-art business incubators within the life sciences. We help researchers to use their data to the benefit of patients and citizens, improving their health. We support and train entrepreneurs in the fields of pharmaceuticals, diagnostics and medical engineering, and act as a bridge between academia, medicine and the business community.